Literature DB >> 8480821

Comorbidity in psychosis at first hospitalization.

S M Strakowski1, M Tohen, A L Stoll, G L Faedda, P V Mayer, M L Kolbrener, D C Goodwin.   

Abstract

OBJECTIVE: The authors sought to determine the prevalence and effects of medical and psychiatric comorbidity on initial outcome in a group of patients experiencing a first episode of psychosis.
METHOD: Patients with a first episode of psychosis who were consecutively admitted to a hospital (N = 102) were examined for the presence of psychiatric and medical disorders. Patients were given psychiatric diagnoses with the use of the Structured Clinical Interview for DSM-III-R and were rated weekly on symptom rating scales. Outcome variables at discharge were final symptom rating scale scores, length of hospitalization, and recovery on the basis of operationalized criteria.
RESULTS: Comorbid diagnoses were present in 52.0% (N = 53) of the patients, and 37.7% (N = 20) had multiple comorbid diagnoses. The most common comorbid diagnosis was substance abuse. Patients with affected psychoses were significantly more likely than those with nonaffective psychoses to have a comorbid substance abuse diagnosis. Patients with psychiatric comorbidity had poorer initial outcomes, while those with medical comorbidity had fewer symptoms at discharge.
CONCLUSIONS: Comorbidity is common and may be a useful predictor of the outcome of a first episode of psychosis.

Entities:  

Mesh:

Year:  1993        PMID: 8480821     DOI: 10.1176/ajp.150.5.752

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

1.  Gender differences in psychotic disorders with concurrent substance use.

Authors:  Carol L M Caton; Haiyi Xie; Robert E Drake; Gregory McHugo
Journal:  J Dual Diagn       Date:  2014

2.  Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.

Authors:  Serge Sevy; Delbert G Robinson; Barbara Napolitano; Raman C Patel; Handan Gunduz-Bruce; Rachel Miller; Joanne McCormack; Beth S Lorell; John Kane
Journal:  Schizophr Res       Date:  2010-05-14       Impact factor: 4.939

3.  Using internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients.

Authors:  Eoin Killackey; Anna Lee Anda; Martin Gibbs; Mario Alvarez-Jimenez; Andrew Thompson; Pamela Sun; Gennady N Baksheev
Journal:  BMC Psychiatry       Date:  2011-05-12       Impact factor: 3.630

4.  Auditory and non-auditory hallucinations in first-episode psychosis: Differential associations with diverse clinical features.

Authors:  Chiara Galletti; Enrico Paolini; Alfonso Tortorella; Michael T Compton
Journal:  Psychiatry Res       Date:  2017-04-24       Impact factor: 3.222

5.  Prevalence of Substance Use in Patients Diagnosed with Schizophrenia.

Authors:  Yasemin Tekin Uludağ; Gülcan Güleç
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

6.  Substance use and cognition in early psychosis.

Authors:  Alissa Pencer; Jean Addington
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

Review 7.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

8.  Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study.

Authors:  Scott W Woods; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Robert Heinssen; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2009-04-21       Impact factor: 9.306

Review 9.  Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.

Authors:  Samantha E Yohn; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2017-09-09       Impact factor: 5.250

Review 10.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.